Company news

Anavex Life Sciences Corp. news in 2022

Anavex Life Sciences Corp.'s news releases, calls and decks from 2022, newest first.

View company

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

December 13, 2022

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 11, 2022

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

December 1, 2022

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

November 30, 2022

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

November 27, 2022

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

November 22, 2022

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022

November 7, 2022

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

November 6, 2022

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022

October 16, 2022

Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy

September 20, 2022

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease

August 22, 2022

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results

August 8, 2022

Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022

August 2, 2022

Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022

August 1, 2022

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

July 30, 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

June 20, 2022

Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

June 7, 2022

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

May 18, 2022

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

May 9, 2022

Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

May 2, 2022

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

April 26, 2022

Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

April 25, 2022

Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference

April 6, 2022

Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit

March 27, 2022

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference

March 14, 2022

Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum

March 8, 2022

Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP

March 3, 2022

Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results

February 8, 2022

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome

February 3, 2022

Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022

February 2, 2022

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome

January 31, 2022

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71

January 9, 2022

Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer

January 5, 2022

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

January 4, 2022

Calls in 2022

Decks in 2022